DAPAGLIFLOZIN
- Strength
- 5 mg/1
- Form
- Tablet
- Class
- Sodium-Glucose Cotransporter 2 Inhibitor
Florida Pharmaceutical Products, LLC
Listed by Ascend Laboratories, LLC
This is a combination product. It is not interchangeable with a single-ingredient medicine containing only one of these.
| Dosage form | Tablet, Film Coated, Extended Release |
|---|---|
| Route | Oral |
| Drug class | Biguanide; Sodium-Glucose Cotransporter 2 Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 67877-621 |
| FDA application | ANDA211563 |
| RxNorm concept | 1593058 |
| Package sizes listed | 3 |
| Marketed since | April 2026 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Florida Pharmaceutical Products, LLC
Teva Pharmaceuticals, Inc.
Zydus Pharmaceuticals USA Inc.
Lupin Pharmaceuticals, Inc.
Ascend Laboratories, LLC
AvKARE
Sandoz Inc
Macleods Pharmaceuticals Limited
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.